New clinical data shows positive long-term performance of Medtronic's CoreValve system

New clinical data presented today at the European Society of Cardiology Congress 2011 demonstrate positive long-term performance for the CoreValve® transcatheter aortic valve replacement system from Medtronic, Inc. (NYSE: MDT). The study monitored patients through four years - the longest follow-up in a published study of any transcatheter aortic valve implantation (TAVI) system to date - and found the CoreValve System maintained its structural integrity and led to positive clinical outcomes.

The study followed 50 patients (average age of 81 years) with native aortic valve disease who were implanted with the 21F CoreValve system in 2005 and 2006 at seven centers in Europe and Canada. The study found:

  • Cardiac survival was 77.9 percent at two years (with overall patient survival of 58.5 percent), and 68.0 percent at four years (with overall patient survival of 45.1 percent).
  • At four years, patients saw substantial improvement in heart failure symptoms: While 87 percent were in NYHA Functional Class III or IV at the beginning of the study, most patients improved to Class I (61 percent) or Class II (22 percent) at four years. In addition, while nearly one-third of patients were classified as having grade 2 or 3 aortic regurgitation at baseline, all patients were classified as having no aortic regurgitation (57 percent) or grade 1 regurgitation (43 percent) at four years.
  • Valve gradient (resistance to blood flow) decreased from 41 mmHg at baseline to 12 mmHg at 30 days and 10 mmHg at four years. Sustained, stable gradient is promising in that it shows the CoreValve performance does not diminish over a 4 year time frame.
  • Valve performance was strong, with no reported frame fractures or valve migrations, and no reported structural valve deteriorations.

"These results reinforce that CoreValve is a sound and stable valve that holds up to real-world use," said Peter den Heijer, M.D., MPH, interventional cardiologist at Amphia Hospital Breda in the Netherlands and an investigator in the study. "Almost more important, however, is that these patients - most of whom were old and very sick at the time of enrollment - saw such positive outcomes, including dramatic improvements in the activity level they could withstand, despite being some of the first patients in the world to undergo TAVI."

Source:

 Medtronic

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Medtronic. (2019, June 19). New clinical data shows positive long-term performance of Medtronic's CoreValve system. News-Medical. Retrieved on May 28, 2022 from https://www.news-medical.net/news/20110829/New-clinical-data-shows-positive-long-term-performance-of-Medtronics-CoreValve-system.aspx.

  • MLA

    Medtronic. "New clinical data shows positive long-term performance of Medtronic's CoreValve system". News-Medical. 28 May 2022. <https://www.news-medical.net/news/20110829/New-clinical-data-shows-positive-long-term-performance-of-Medtronics-CoreValve-system.aspx>.

  • Chicago

    Medtronic. "New clinical data shows positive long-term performance of Medtronic's CoreValve system". News-Medical. https://www.news-medical.net/news/20110829/New-clinical-data-shows-positive-long-term-performance-of-Medtronics-CoreValve-system.aspx. (accessed May 28, 2022).

  • Harvard

    Medtronic. 2019. New clinical data shows positive long-term performance of Medtronic's CoreValve system. News-Medical, viewed 28 May 2022, https://www.news-medical.net/news/20110829/New-clinical-data-shows-positive-long-term-performance-of-Medtronics-CoreValve-system.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
DreaMed Diabetes and Medtronic enter strategic collaboration